Teva Pharmaceutical Industries (TEVA) Cash from Financing Activities: 2009-2025
Historic Cash from Financing Activities for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to -$453.0 million.
- Teva Pharmaceutical Industries' Cash from Financing Activities was N/A to -$453.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 billion, marking a year-over-year change of. This contributed to the annual value of -$1.8 billion for FY2024, which is 6.38% up from last year.
- As of Q3 2025, Teva Pharmaceutical Industries' Cash from Financing Activities stood at -$453.0 million, which was down 7,650.00% from $6.0 million recorded in Q2 2025.
- Teva Pharmaceutical Industries' 5-year Cash from Financing Activities high stood at $6.0 million for Q2 2025, and its period low was -$1.7 billion during Q1 2025.
- Its 3-year average for Cash from Financing Activities is -$589.5 million, with a median of -$576.0 million in 2023.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Cash from Financing Activities slumped by 35,400.00% in 2023 and then soared by 100.62% in 2025.
- Quarterly analysis of 5 years shows Teva Pharmaceutical Industries' Cash from Financing Activities stood at -$501.0 million in 2021, then plummeted by 41.92% to -$711.0 million in 2022, then rose by 18.99% to -$576.0 million in 2023, then dropped by 17.01% to -$674.0 million in 2024, then spiked by 100.62% to -$453.0 million in 2025.
- Its last three reported values are -$453.0 million in Q3 2025, $6.0 million for Q2 2025, and -$1.7 billion during Q1 2025.